Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Karen O Dixon"'
Autor:
Alfred Zippelius, Mélanie Buchi, Richard Klar, Julia Festag, Sven Michel, Frank Jaschinski, Sebastian Kobold, Abhishek S Kashyap, Johannes vom Berg, Laura Fernandez-Rodriguez, Chiara Cianciaruso, Ruben Bill, Marcel P Trefny, Nicole Kirchhammer, Rainer H Kohler, Elham Jones, Andre Maaske, Karen O Dixon, Mikael J Pittet
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 5 (2023)
Background Although immune checkpoint inhibitors have been a breakthrough in clinical oncology, these therapies fail to produce durable responses in a significant fraction of patients. This lack of long-term efficacy may be due to a poor pre-existing
Externí odkaz:
https://doaj.org/article/78cf6c8515374d7f847b8913a986bde6
Autor:
Ruihan Tang, Nandini Acharya, Ayshwarya Subramanian, Vinee Purohit, Marcin Tabaka, Yu Hou, Danyang He, Karen O. Dixon, Connor Lambden, Junrong Xia, Orit Rozenblatt-Rosen, Raymond A. Sobel, Chao Wang, Aviv Regev, Ana C. Anderson, Vijay K. Kuchroo
Publikováno v:
Sci Immunol
Dendritic cells (DCs) sense environmental cues and adopt either an immune-stimulatory or regulatory phenotype, thereby fine-tuning immune responses. Identifying endogenous regulators that determine DC function can thus inform the development of thera
Autor:
Laura Fernandez-Rodriguez, Chiara Cianciaruso, Ruben Bill, Marcel P Trefny, Richard Klar, Nicole Kirchhammer, Mélanie Buchi, Julia Festag, Sven Michel, Rainer H Kohler, Elham Jones, Andre Maaske, Abhishek S Kashyap, Frank Jaschinski, Karen O Dixon, Mikael J Pittet, Alfred Zippelius
Publikováno v:
Journal for ImmunoTherapy of Cancer. 11:e006714
BackgroundAlthough immune checkpoint inhibitors have been a breakthrough in clinical oncology, these therapies fail to produce durable responses in a significant fraction of patients. This lack of long-term efficacy may be due to a poor pre-existing
Autor:
Orit Rozenblatt-Rosen, Markus A. Schramm, Aviv Regev, Marcin Tabaka, Ana C. Anderson, Karen O. Dixon, Ruihan Tang, Vijay K. Kuchroo, Danielle Dionne, Sheng Xiao
Publikováno v:
Nature
T cell immunoglobulin and mucin-containing molecule 3 (TIM-3), first identified as a molecule expressed on interferon-γ producing T cells1, is emerging as an important immune-checkpoint molecule, with therapeutic blockade of TIM-3 being investigated
Autor:
Kouichiro Goto, Vijay K. Kuchroo, Manu Rangachari, Hitoshi Okada, Chao Wang, Orit Rosenblatt-Rosen, Elena Christian, Tak W. Mak, Chen Zhu, Karen O. Dixon, Kathleen Newcomer, Aviv Regev, Guangxiang Gu, Meromit Singer, Huiyuan Zhang, Markus A. Schramm, Sheng Xiao, Sarah Zaghouani
Publikováno v:
Science Advances
Tim-3 adaptor protein Bat3 regulates T cell terminal differentiation and exhaustion in an mTORC2-dependent manner.
T cell exhaustion has been associated with poor prognosis in persistent viral infection and cancer. Conversely, in the context of
T cell exhaustion has been associated with poor prognosis in persistent viral infection and cancer. Conversely, in the context of
Autor:
Giulia Escobar, Nandini Acharya, Meromit Singer, Huiyuan Zhang, Marcus Bosenberg, Vijay K. Kuchroo, Karen O. Dixon, Davide Mangani, Aviv Regev, Geoffrey Fell, Elena Christian, Junrong Xia, Donna Neuberg, Orit Rozenblatt-Rosen, Michelle Ferreira, Asaf Madi, Shai Dulberg, Katherine Tooley, Max Klapholz, Ana C. Anderson
Publikováno v:
PMC
Summary Identifying signals in the tumor microenvironment (TME) that shape CD8+ T cell phenotype can inform novel therapeutic approaches for cancer. Here, we identified a gradient of increasing glucocorticoid receptor (GR) expression and signaling fr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b28f52a69ee51295058c26393d17ad06
https://hdl.handle.net/1721.1/133832
https://hdl.handle.net/1721.1/133832
Autor:
Vijay K. Kuchroo, Karen O. Dixon
Publikováno v:
Cell Research
Cytokines were the first modern immunotherapies to produce durable responses in patients with advanced cancer, but they have only modest efficacy and limited tolerability
Autor:
Max Klapholz, Karen O. Dixon, Vijay K. Kuchroo, Ana C. Anderson, Elena Christian, Davide Mangani, Geoffrey Fell, Donna Neuberg, Junrong Xia, Katherine Tooley, Aviv Regev, Nandini Acharya, Orit Rozenblatt-Rosen, Asaf Madi, Meromit Singer, Huiyuan Zhang
Identifying signals in the tumor microenvironment (TME) that promote CD8+ T cell dysfunction can inform improved therapeutic approaches for cancer. Here, we identify that Nr3c1, the gene encoding the glucocorticoid receptor (GR), is highly expressed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5904fdc6c64f16b6af6c1bbbe8a13ba
Publikováno v:
Nature Genetics. 50:1640-1641
A new study identifies loss-of-function mutations in HAVCR2, which encodes TIM-3, in patients with a rare cutaneous T cell lymphoma associated with aberrant immunological activation. These mutations lead to loss of the TIM-3 immunological checkpoint,
Publikováno v:
European Journal of Immunology. 45:1736-1747
IL-35 is a cytokine of the IL-12 family, existing as a heterodimer of IL-12p35 and Ebi3. IL-35 has anti-inflammatory properties and is produced by regulatory T cells in humans and mice, where it is required for optimal suppression of immune responses